Stereotactic Body Radiation Therapy (SBRT)-Induced 68 Ga-PSMA PET Bone Flare.

Clin Nucl MedMar 31, 2026 (epub)

Valentina Marulanda-Corzo, Preeti Kakkar, Arman Sharbatdaran et al.

✦ AI-curated · Sources linked

Case in brief

A 65-year-old man with oligometastatic prostate cancer underwent radical prostatectomy and SBRT to a right pubic bone metastasis. Four weeks later, PSMA PET showed greater extent and intensity of uptake at the treated site, although PSA had fallen 92% (8.5 to 0.7 ng/mL) and no new lesions were seen. Subsequent imaging showed resolution of uptake at that site, consistent with bone flare, but also multiple new bone metastases; PSA had risen to 2.8 ng/mL, indicating disease progression.

What made this case unusual

The treated bone lesion showed increased PSMA uptake soon after SBRT despite a marked PSA decline and no new lesions, then resolved on later imaging. The authors describe this as SBRT-induced bone flare.

Diagnostic / clinical pearl

Increased uptake at a recently irradiated bone metastasis on early posttreatment PSMA PET may reflect bone flare; interpret it alongside PSA and subsequent imaging.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.